Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499497 · ClinicalTrials.gov registry record · Phase 2
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
- 4
- Study locations
NCT02499497 is a Phase 2 study of Prostate Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 114 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02499497, a Phase 2 study of Prostate Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. Androgens are a group of hormones that play a role in male traits and reproductive activity. The names of the study interventions involved in this study are: \- LY2452473
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY2452473
Study Locations (4)
Massachusetts
- Beth Israel Deaconess Medical Center (Referring site only) - Boston
- Brigham and Women's Hospital - Boston
Florida
- University of Florida - Gainesville
Maryland
- John Hopkins Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2016-02-29 |
| Est. Completion | 2020-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499497
The ClinicalTrials.gov registry entry for NCT02499497 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02499497 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT02499497 about?
NCT02499497 is a clinical study titled "A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer". This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. A...
What is the current status of trial NCT02499497?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2016-02-29. Estimated completion is 2020-10-31.
What conditions does trial NCT02499497 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02499497?
The interventions under investigation include: Placebo (DRUG), LY2452473 (DRUG).
Who is sponsoring clinical trial NCT02499497?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02499497 being conducted?
This trial has 4 study locations across Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.